Welcome to Markets Desk, your midday read on what's moving markets and policy.
Corporate America is entering earnings season with unusual swagger. More companies than ever have issued upbeat guidance on future profits, a signal that despite macro headwinds, management teams see margin resilience ahead. Watch whether that optimism holds once the actual numbers start hitting the tape this week.
Shifting to pharma, Pfizer's six percent dividend yield is drawing attention from income investors who aren't spooked by the patent cliff narrative. The argument is straightforward — the balance sheet can sustain the payout even as blockbuster exclusivities roll off. Whether the market re-rates the stock depends on how aggressively Pfizer deploys its pipeline capital over the next two years.
And in Washington, President Trump has tapped Jay Clayton, currently serving as director of national intelligence, to lead what the administration is calling a Super Intelligence Force — essentially a government task force on artificial intelligence. Clayton's background is regulatory, not technical, which raises real questions about how this body will engage with the AI executives Trump hosted at the White House just last week.
That's the tape. Markets Desk, signing off the floor.
